This is a preview of subscription content, log in via an institution to check access.
References
Miossec P. Cytokine-induced autoimmune disorders. Drug Saf 1997 Aug; 17(2): 93–104
Kapsenberg ML, Wierenga EA, Van Der Heijden FL, et al. Atopic dermatitis and CD4+ atopen-specific Th2 lymphocytes. Eur J Dermatol 1992; 8: 601–7
Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24(1): 38–47
Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676–80
Myers LW, Ellison GW. The peculiar difficulties of therapeutic trials for multiple sclerosis. Neurol Clin 1990; 8(1): 119–41
DMARDs, splenectomy or colony-stimulating factors for neutropenia in Felty’s syndrome. Drug Ther Perspect 1997 Sep 15; 10(6): 6–9
Hoshina Y, Moriuchi J, Nakamura Y, et al. CD4+ T cell mediated leukopenia of Felty’s syndrome successfully treated with granulocyte colony stimulating factor and methotrexate. Arthritis Rheum 1994; 37(2): 298–9
Rights and permissions
About this article
Cite this article
Caution needed when administering cytokines to patients with pre-existing autoimmune disorders. Drugs Ther. Perspect 11, 12–13 (1998). https://doi.org/10.2165/00042310-199811110-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199811110-00005